SBFM, SBFMW · CIK 0001402328 · operating
Sunshine Biopharma operates as a biopharmaceutical company developing prescription and over-the-counter pharmaceutical products across oncology, antiviral, and general therapeutic areas. The company maintains two primary business segments: Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. Its pipeline includes SBFM-PL4, a protease inhibitor in development for SARS coronavirus infections; Adva-27a, a small-molecule chemotherapy candidate for pancreatic cancer; and K1.1 mRNA, a lipid nanoparticle formulation for liver cancer treatment.
The company's commercial product portfolio encompasses a range of generic prescription medications addressing indications including osteoporosis, cardiovascular disease, hypertension, diabetes, oncology, and various other conditions. Its over-the-counter offerings include Essential 9 amino acid capsules, calcium-vitamin D supplements, and amino acid products such as L-Citrulline and Taurine.
Sunshine Biopharma is incorporated in Colorado and headquartered in Fort Lauderdale, Florida, with 52 full-time employees. The company is listed on Nasdaq and operates in both the United States and Canada.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-7.32 | $-7.32 | -3752.6% | |
| 2023 | $-0.19 | $-0.19 | +89.2% | |
| 2022 | $-1.76 | $-1.76 | +63.0% | |
| 2021 | — | $-4.76 | -47500.0% | |
| 2020 | — | $-0.01 | +93.3% | |
| 2019 | — | $-0.15 | -275.0% | |
| 2018 | — | $-0.04 | — | |
| 2017 | — | $0.00 | +100.0% | |
| 2016 | — | $-0.01 | +0.0% | |
| 2015 | — | $-0.01 | +66.7% | |
| 2014 | — | $-0.03 | +25.0% | |
| 2013 | — | $-0.04 | -300.0% | |
| 2012 | — | $-0.01 | +50.0% | |
| 2011 | — | $-0.02 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-04-01 | 0001683168-25-002184 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0001683168-24-001818 | SEC ↗ |
| 2022-12-31 | 2023-04-04 | 0001683168-23-002128 | SEC ↗ |
| 2021-12-31 | 2022-03-21 | 0001683168-22-001788 | SEC ↗ |
| 2020-12-31 | 2021-03-30 | 0001654954-21-003507 | SEC ↗ |
| 2019-12-31 | 2020-05-01 | 0001654954-20-004731 | SEC ↗ |
| 2018-12-31 | 2019-04-12 | 0001654954-19-004354 | SEC ↗ |
| 2017-12-31 | 2018-04-02 | 0001654954-18-003495 | SEC ↗ |
| 2016-12-31 | 2017-04-17 | 0001654954-17-003365 | SEC ↗ |
| 2015-12-31 | 2016-03-25 | 0001354488-16-006700 | SEC ↗ |
| 2014-12-31 | 2015-03-11 | 0001354488-15-001081 | SEC ↗ |
| 2013-12-31 | 2014-03-19 | 0001354488-14-001275 | SEC ↗ |
| 2012-12-31 | 2013-03-15 | 0001354488-13-001224 | SEC ↗ |
| 2011-12-31 | 2012-03-19 | 0001354488-12-001221 | SEC ↗ |
| 2010-12-31 | 2011-03-30 | 0001013596-11-000008 | SEC ↗ |
| 2009-07-31 | 2009-10-30 | 0001079974-09-000803 | SEC ↗ |